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INTRODUCTION
Cisplatin -based chemotherapy is beneficial as the
first line treatment of locally advanced or metas-
tatic non-small cell lung cancer (NSCLC) (1). Re-
cent phase III trials showed that platinum agents
in combination with the third-generation che-
motherapeutic agents had the same efficacy with
each other (2 - 4). On the other hand, the effect of
second- or third- line treatment in first line - failed
or relapsed NSCLC is limited. Docetaxel is the most
evidence -based in the second line treatment of
NSCLC (5-7). However, these studies were per-
formed during the second-generation regimen,
and docetaxel had a possibility of cross -resistance
against paclitaxel, which is the most commonly
used drug in the first line treatment (8). Pemetrexed
and erlotinib were also good candidates for the sec-
ond line chemotherapy in NSCLC (9, 10). But there
is no more “evidence-based” treatment as second-
or third- line therapy in NSCLC. Therefore, the es-
tablishment of another second- or third-line ther-
apy is needed in NSCLC.
Gemcitabine is an antimetabolite and one of the
standard drugs in the first line of treatment for lo-
cally advanced or metastatic NSCLC (2-4). Gemcit-
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abine is also expected for the second line drug. Six
phase II trials showed the response rate of 7 -21%
and the median survival time of 22 -36 weeks, and
these results are almost equivalent to those of do-
cetaxel (7).
UFT is an oral antimetabolite composed of tega-
fur and uracil at a fixed molar ratio of 1 : 4. Tega-
fur is changed to 5-FU in the body. FdUMP which
is an active metabolite of 5 -FU inhibits thymidylate
synthase, and DNA synthesis is inhibited. Although
single agent chemotherapy of UFT showed a re-
sponse rate of 6.3% in advanced NSCLC (11), re-
cent randomized phase III trials showed that post-
operative adjuvant chemotherapy using 250 mg/m2
of daily UFT improved overall survival and progres-
sion free survival significantly when compared with
observation (12).
Gemcitabine is uptaken to cytosol by a transporter
protein called the nucleoside transporter (13). A
basic experiment showed that the expression of the
nucleoside transporter was increased in the tumor
cells treated with inhibitor of thymidylate synthase,
such as 5-FU (14). Thus, there is a possibility that
tumors treated with UFT became highly sensitive
to gemcitabine because gemcitabine is over -uptaken
to cytosol by over expression of the nucleoside
transporter.
Gemcitabine plus UFT combination therapy is
considered for their synergic effect in NSCLC. A
phase I trial of gemcitabine plus UFT combination
therapy in a first line setting in patients with NSCLC
recommends 200 mg/m2 of UFT b.i.d for days 1 -14
with 900 mg/m2 of gemcitabine on days 8 and 15
every three weeks (15). A phase II trial of gemcit-
abine plus UFT combination therapy in a first line
setting showed the response rate of 41% and the
median survival time of 13.2 months (16). The most
common grade 3-4 toxicity was neutropenia (57%)
(16). On the other hand, subjective side effects such
as alopecia, neuropathy, nausea, and vomiting were
few. Moreover, UFT and gemcitabine are easily ad-
ministered orally, or by intravenous drip infusion
in 30 minutes. Therefore, from the viewpoint of
QOL, both drugs are suitable for outpatient settings
as second- or third- line therapy in metastatic
NSCLC that is difficult to cure. However, there are
few issues described gemcitabine plus UFT combi-
nation chemotherapy as second- or third- line ther-
apy in NSCLC. With this background, we planned
a feasibility study to evaluate the feasibility of gem-
citabine plus UFT combination chemotherapy as
second- or third- line therapy in NSCLC.
PATIENTS AND METHODS
Eligibility
Eligible patients had histologically or cytologically
proven locally advanced or metastatic NSCLC and
had received one or two previous cytotoxic chemo-
therapy regimens and had failed or relapsed. Gefit-
inib was counted as one regimen when it was used
as a second line regimen. Patients had histologi-
cally or cytologically defined NSCLC ; stage IV or
unresectable stage IIIB ; age 20 years or over ; East-
ern Cooperative Oncology Group (ECOG) perform-
ance status 0 -1 ; evaluable or measurable lesion ;
adequate organ function (white blood cells3000/
μl, absolute neutrophil count 1500/μl, platelets
100000/μl, hemoglobin 9.5 g/dl, serum trans-
aminases2.5 times the institutional upper limit of
normal, serum total bilirubin1.5 times institutional
the upper limit of normal, serum creatinine insti-
tutional upper limit of normal, a life expectancy of
at least three months ; and written informed con-
sent.
Patients were considered ineligible if they had
interstitial pneumonia or pulmonary fibrosis on a
chest X-ray, superior vena cava syndrome, uncon-
trollable diabetes mellitus, severe liver dysfunction
with icterus, angina pectoris, acute myocardial in-
farction within three months, severe infection, se-
vere psychiatric disease, pregnancy, lactating, dou-
ble cancer within five years, or severe heart disease.
The ethics and research committee of our hospital
approved this study.
Treatment plan
All treatment was administered on an outpatient
setting. Gemcitabine (900 mg/m2) was dissolved
in 200 ml of physiological saline and administered
by intravenous drip infusion in 30 minutes on days
8 and 15. Dexamethasone (8 mg) was dissolved in
50 ml of physiological saline and administered by
intravenous drip infusion just before the admini-
stration of gemcitabine. UFT (tegafur 250 mg/m2/
day) was administered orally twice a day in the
form of a 100 mg capsule (100 mg of tegafur plus
224 mg of uracil) from days 1 to 14. The dose was
rounded up or down as follows : 300 mg/body/day
for a body surface area of1.39 m2, 400 mg/body/
day for a body surface area of 1.40 m2 and 1.79
m2, 500 mg/body/day for a body surface area of
1.8 m2.
On days 8 and 15, a complete blood count was
performed, and the treatment was delayed one week
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in case of white blood cells2000/μl, absolute neu-
trophil count 1000/μl, platelets 75000/μl, and
non-hematologic toxicity (except nausea, vomiting,
appetite loss, fatigue and alopecia) grade 3. The
treatment regimen was repeated every 3 weeks and
at least 3 cycles were administered unless disease
progression or grade 4 non-hematologic toxicity
occurred (grade 2 for interstitial pneumonia). On
day 22 (day 1 of the next cycle), a complete blood
count, biochemical examination, and chest X-ray
were performed, and the next cycle was delayed
one week in case of white blood cells2000/μl, ab-
solute neutrophil count1000/μl, platelets75000/
μl, serum transaminases2.5 times the institutional
upper limit of normal, serum total bilirubin 1.5
times the institutional upper limit of normal, serum
creatinineinstitutional upper limit of normal, and
non-hematologic toxicity (except nausea, vomiting,
appetite loss, fatigue and alopecia)grade 3. If the
treatment delay was continued more than 21 days,
the protocol study was cancelled.
The dose of gemcitabine was reduced by 200
mg/m2 in case of white blood cells2000/μl, abso-
lute neutrophil count 1000/μl, platelets 50000/
μl, and non-hematologic toxicity (except nausea,
vomiting, appetite loss, fatigue and alopecia) grade
3 in the prior cycle. The dose was not reduced un-
til a cycle was completed. The dose of UFT was not
changed during the study. When the dose of gem-
citabine was reduced to less than 500 mg/m2, the
protocol study was cancelled.
Evaluation
The primary end points of this study were safety,
feasibility, and the relative dose intensity of che-
motherapeutic agents. The secondary end points
were response rate and disease control rate. The
relative dose intensity was calculated as follows :
received dose intensity [totally administered dose
of drug (mg) / total treatment duration (weeks)] /
planned dose intensity [totally planned dose of drug
(mg) / totally planned duration (weeks)]. The days
of additional hospital visits due to any adverse event
were also counted as the indicator of feasibility of
the regimen. All patients received a computed to-
mography (CT) scan of the thorax and abdomen,
magnetic resonance images (MRI) of the brain, and
a radioisotopic bone scan before the treatment
started. After the initial baseline imaging, an evalu-
ation of response rates was performed after 3 cy-
cles of treatment using the same imaging exami-
nation. The response rate was calculated accord-
ing to the RECIST criteria (17). Any adverse event
was graded according to the National Cancer Insti-
tute-Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0.
RESULTS
Patients’ characteristics
Between October 2005 and December 2006, fif-
teen eligible patients with first or second line-failed
or relapsed NSCLC were enrolled. The median age
was 57 years (range : 39 -79 years). ECOG Perform-
ance status was 0 in 7 patients and 1 in 8 patients.
Twelve patients had stage IV disease and three pa-
tients had stage IIIB disease. Thirteen patients had
adenocarcinoma and two patients had undifferenti-
ated NSCLC. The first line therapy was carboplatin
plus paclitaxel therapy for 13 patients, cisplatin plus
vinorelbine for one patient, and single agent do-
cetaxel therapy for one patient. The previous ther-
apy just before gemcitabine plus UFT therapy was
gefitinib for 8 patients, carboplatin plus paclitaxel
for 5 patients and docetaxel for 2 patients. Five
patients had previously received palliative radio-
therapy and 3 patients had received gamma knives
for brain metastasis. There was no patient who had
received both Linac and gamma knife therapies.
These characteristics are shown in Table 1.
Table 1 Patient characteristics
Gender
Male / Female 9 / 6
Age
Median (range) 57 (39-79)
Performance status (ECOG*)
0/1 7 / 8
Stage
IIIB / IV 3 / 12
Histology
Adenocarcinoma / others 13 / 2
First line therapy
Carboplatin plus paclitaxel / other chemotherapy 13 / 2
Previous therapy just before gemcitabine plus UFT therapy
Gefitinib / carboplatin plus paclitaxel / docetaxel 8 / 5 / 2
Previous palliative radiotherapy
None / Linac / gamma knives for brain metastasis 7 / 5 / 3
* : Eastern Cooperative Oncology Group
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Response
Fourteen patients among 15 eligible patients were
evaluable for response. For one patient it was im-
possible to evaluate response because the treatment
had to be cancelled after one cycle due to toxicity.
One patient’s disease became remarkably progres-
sive after 2 cycles of treatment, and the treatment
was cancelled because of the patient’s preference.
One patient achieved a partial response (1/15, 6.7%)
(Table 2). Nine patients showed stable disease (9/
15, 60.0%), and four patients showed progressive
disease (4/15, 26.7%) (Table 2). Disease control
rate was 66.7% (10/15).
Feasibility and toxicity
All patients were evaluable for toxicity and feasi-
bility. A total of 59 cycles was administered in 15
patients. The median number of cycles was 3
(range : 1 -7). The median interval between cycles
was 21 days (range : 21 -28). The number of unex-
pected visits to the hospital due to adverse events
was only 3 in total 59 cycles. The mean and the me-
dian relative dose intensity of gemcitabine were
0.93 and 1 (range : 0.75 -1), respectively. The mean
and the median relative dose intensity of UFT were
0.97 and 1 (range : 0.75 -1), respectively. These pro-
files of feasibility are shown in Table 2.
The main toxicity was hematologic toxicity. Grade
2 neutropenia occurred in 8 patients. However,
Grade 3 neutropenia was shown only in one pa-
tient and treatment was delayed. Anemia occurred
with Grade 1 in 7 patients and Grade 2 in 4 pa-
tients. Thrombocytopenia was relatively mild with
Grade 1 in 8 patients and Grade 2 in 1 patient. One
patient showed Grade 3 elevation of transaminases
after the first cycle of treatment and the second
cycle of treatment was cancelled because of the
patient’s preference. In the subjective side effects,
fatigue was one of the major symptoms in this treat-
ment with Grade 1 in 4 patients and Grade 2 in 4
patients. Appetite loss was shown in 6 patients
with Grade 1, and 2 patients in Grade 2. However,
nausea and vomiting was minimal. Grade 1 alope-
cia occurred in 5 patients, but they received che-
motherapy containing paclitaxel or docetaxel just
before gemcitabine plus UFT treatment. There was
no Grade 4 toxicity. No patient needed hospitaliza-
tion during treatment. No patient died due to tox-
icity. The profiles of toxicity are shown in Table 3.
DISCUSSION
In this pilot study, we showed the feasibility and
Table 2 Treatment characteristics
Total number of cycles 59
Median number of cycles (range) 3 (1-7)
Number of administered courses
1 1
2 1
3 7
4 0
5 2
6 3
7 1
Median interval days between cycles (range) 21 (21-28)
Number of unexpected visit to the hospital due to adverse event
3 (in 59 cycles)
Relative dose intensity of gemcitabine
MeanSD* 0.930.10
Median (range) 1 (0.75-1)
Relative dose intensity of UFT
MeanSD 0.970.07
Median (range) 1 (0.75-1)
Response
CR 0
PR 1
SD 9
PD 4
* : standard deviation
Table 3 Hematologic and non-hematologic toxicities (n=15)
Grade*
Toxicity 1 2 3 4
Hematologic toxicity
Leucopenia 7 5 - -
Neutropenia - 8 1 -
Anemia 7 4 - -
Thrombocytopenia 8 1 - -
Non-hematologic toxicity
Transaminases - - 1 -
Alopecia 5 - - -
Appetite loss 6 2 - -
Diarrhea 2 1 - -
Fever up 1 - - -
Fatigue 4 4 - -
Nausea 2 1 - -
Skin eruption - 1 - -
Stomatitis 1 - - -
Vomiting 1 - - -
* : National Cancer Institute-Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0.
: Data were shown in the number of patients.
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toxicity of gemcitabine plus UFT combination che-
motherapy. Gemcitabine plus UFT combination che-
motherapy was well - tolerated in second- or third-
line setting in NSCLC. Because there were very
few Grade 3-4 adverse events, the number of unex-
pected visits to the hospital due to adverse events
was quite few during the treatment (Table 2, 3).
Therefore, treatment delay was almost free and the
relative dose intensities of both gemcitabine and
UFT were very high (Table 2). These results of fea-
sibility were especially good compared with other
second line regimens (5 -7, 9, 10). Moreover, 10
out of 15 (66.7%) patients’ disease were controlled
(CR+PR+SD) after 3 cycles of treatment, and we
could repeat the treatment for 5 cycles in 2 patients,
6 cycles in 3 patients, and 7 cycles in one patient
(Table 2). Less toxicity also helped the repeat of
cycles. We also found that the toxicity was not ac-
cumulated after the repeat of cycles. There were a
few subjective side effects such as alopecia and eme-
sis (Table 3), and gemcitabine and UFT are easily
administered by a 30-minute intravenous drip in-
fusion or orally. Therefore, from a QOL viewpoint,
gemcitabine plus UFT combination chemotherapy
were considered suitable for an outpatient setting.
High disease control rate and less toxicity suggested
the potential of gemcitabine and UFT combination
chemotherapy for an outpatient setting as second-
or third- line therapy in metastatic NSCLC that is
difficult to cure.
Although 400 mg/m2 of UFT was administered
in a phase II trial of first line -gemcitabine plus
UFT combination chemotherapy (16), we adminis-
tered 250 mg/m2 of UFT because recent random-
ized phase III trials showed that postoperative ad-
juvant chemotherapy using 250 mg/m2 of daily UFT
improved overall survival and progression free sur-
vival significantly compared with observation (12).
We assumed that 250 mg/m2 of UFT was enough
for efficacy. We thought the meaning of UFT in
the gemcitabine plus UFT combination therapy was
not the cytotoxic agent but the sensitizer of gem-
citabine through the effect of overexpression of the
nucleoside transporter (13, 14). We considered
that 250 mg/m2 of UFT might be enough for the
sensitizer.
One patient showed Grade 3 elevation of trans-
aminases and the treatment was cancelled because
of the patient’s preference. This patient had expe-
rienced Grade 3 elevation of transaminases in the
previous treatment (gefitinib), but had no hepatitis
virus. Gemcitabine, especially in combination ther-
apy, is known to have liver toxicity. A previous re-
port of a phase II trial of gemcitabine plus vinorel-
bine therapy showed 22.5% of Grade 3-4 elevation
of transaminase (18). It is said that liver dysfunc-
tion caused by gemcitabine is transient and revers-
ible (18). But we have to remark that liver toxicity
can also be found in the gemcitabine plus UFT
therapy
A recent phase II trial reported by Chen, et al.
showed the effectiveness of gemcitabine plus uracil -
tegafur combination chemotherapy in NSCLC pa-
tients failing previous chemotherapy (19). In the
study, the response rate achieved 15.6%, and Grade
3-4 hematologic toxicities were observed in 6.7 -
17.8% of patients (19). On the other hand, non-
hematologic toxicities were minimal and mild (19).
The profile of efficacy and toxicity in our study was
similar to Chen’s result. The treatment schedule
was different between our study and Chen’s study
(19). We administered UFT on days 1-14 and gem-
citabine on days 8 and 15 every three weeks. On
the other hand, Chen, et al. administered UFT on
days 1-14 and gemcitabine on days 1 and 8 every
three weeks (19). We considered that the pretreat-
ment of tumor cells with UFT caused the increase
of sensitivity against gemcitabine through the over-
expression of nucleoside transporter in tumor cells
(13, 14). Therefore, we recommend administering
gemcitabine on days 8 and 15 after the initial ad-
ministration of UFT.
The limitation of the study was the sample size
in the feasibility study. Thus, a phase II trial of
gemcitabine plus UFT combination chemotherapy
using our schedule would be required to confirm
the efficacy. In conclusion, gemcitabine plus UFT
combination chemotherapy as second- or third-
line therapy in NSCLC was well - tolerated with less
toxicity. This regimen would be one of the hopeful
treatments in second or third line settings for pa-
tients with locally advanced or metastatic NSCLC.
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